|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM155374877 |
003 |
DE-627 |
005 |
20231223072008.0 |
007 |
tu |
008 |
231223s2005 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0518.xml
|
035 |
|
|
|a (DE-627)NLM155374877
|
035 |
|
|
|a (NLM)15893691
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Ozdemir, Oner
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells
|
264 |
|
1 |
|c 2005
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 14.07.2005
|
500 |
|
|
|a Date Revised 21.11.2008
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a In vitro comparisons of induction of perforin (PFP), granzyme B (GRB), production of cytokines, and cell-mediated cytotoxicity by interleukin-2 (IL-2), interleukin-15 (IL-15), or combinational IL-2/IL-15-induced lymphokine-activated killer cells were studied in this study. Whereas IL-2-induction was associated with a decrease in cultured cell population over a 7-day period, IL-15 alone or in combination with IL-2 resulted in significant increase including cytotoxic T lymphocytes and subsets of CD56+ lymphocytes, particularly cytokine-induced killer and cytolytic natural killer-T lymphocytes. The overall PFP, GRB, and tumor necrosis factor-alpha expression in different subtypes were also significantly higher with IL-15 alone or in combination with IL-2 induction with resultant superior cytotoxicity compared to IL-2 treatment. There was no significant advantage of addition of IL-2 over IL-15 induction. These results offer further information on the cytotoxic potency of these cytokines and their mechanisms of action implicating potential use of IL-15 as part of cytokine adoptive immunotherapy
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
7 |
|a Interleukin-15
|2 NLM
|
650 |
|
7 |
|a Interleukin-2
|2 NLM
|
650 |
|
7 |
|a Lymphokines
|2 NLM
|
650 |
|
7 |
|a Membrane Glycoproteins
|2 NLM
|
650 |
|
7 |
|a Pore Forming Cytotoxic Proteins
|2 NLM
|
650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
650 |
|
7 |
|a Perforin
|2 NLM
|
650 |
|
7 |
|a 126465-35-8
|2 NLM
|
650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
650 |
|
7 |
|a 82115-62-6
|2 NLM
|
650 |
|
7 |
|a GZMB protein, human
|2 NLM
|
650 |
|
7 |
|a EC 3.4.21.-
|2 NLM
|
650 |
|
7 |
|a Granzymes
|2 NLM
|
650 |
|
7 |
|a EC 3.4.21.-
|2 NLM
|
650 |
|
7 |
|a Serine Endopeptidases
|2 NLM
|
650 |
|
7 |
|a EC 3.4.21.-
|2 NLM
|
700 |
1 |
|
|a Savaşan, Süreyya
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 115(2005), 3 vom: 31. Juni, Seite 240-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:115
|g year:2005
|g number:3
|g day:31
|g month:06
|g pages:240-9
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 115
|j 2005
|e 3
|b 31
|c 06
|h 240-9
|